JP2019512695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512695A5 JP2019512695A5 JP2018548412A JP2018548412A JP2019512695A5 JP 2019512695 A5 JP2019512695 A5 JP 2019512695A5 JP 2018548412 A JP2018548412 A JP 2018548412A JP 2018548412 A JP2018548412 A JP 2018548412A JP 2019512695 A5 JP2019512695 A5 JP 2019512695A5
- Authority
- JP
- Japan
- Prior art keywords
- βig
- treatment
- pancreatic
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 claims 2
- 108700006666 betaIG-H3 Proteins 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 230000003472 neutralizing effect Effects 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims 1
- 108050001894 Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000008092 positive effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021067346A JP7569741B2 (ja) | 2016-03-15 | 2021-04-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
| JP2023003171A JP2023052360A (ja) | 2016-03-15 | 2023-01-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305276.4 | 2016-03-15 | ||
| EP16305276 | 2016-03-15 | ||
| PCT/EP2017/056150 WO2017158043A1 (en) | 2016-03-15 | 2017-03-15 | Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatement of such disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067346A Division JP7569741B2 (ja) | 2016-03-15 | 2021-04-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512695A JP2019512695A (ja) | 2019-05-16 |
| JP2019512695A5 true JP2019512695A5 (enExample) | 2020-04-09 |
| JP6903680B2 JP6903680B2 (ja) | 2021-07-14 |
Family
ID=55588194
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548412A Active JP6903680B2 (ja) | 2016-03-15 | 2017-03-15 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
| JP2021067346A Active JP7569741B2 (ja) | 2016-03-15 | 2021-04-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
| JP2023003171A Pending JP2023052360A (ja) | 2016-03-15 | 2023-01-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021067346A Active JP7569741B2 (ja) | 2016-03-15 | 2021-04-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
| JP2023003171A Pending JP2023052360A (ja) | 2016-03-15 | 2023-01-12 | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11740243B2 (enExample) |
| EP (2) | EP3430404B1 (enExample) |
| JP (3) | JP6903680B2 (enExample) |
| KR (2) | KR102408161B1 (enExample) |
| DK (2) | DK3779447T3 (enExample) |
| ES (2) | ES2911038T3 (enExample) |
| FI (1) | FI3779447T3 (enExample) |
| HR (2) | HRP20220335T1 (enExample) |
| PL (2) | PL3430404T3 (enExample) |
| WO (1) | WO2017158043A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2911038T3 (es) * | 2016-03-15 | 2022-05-17 | Inst Nat Sante Rech Med | Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad |
| US20210340240A1 (en) * | 2018-10-18 | 2021-11-04 | INSERM (Institut National de la Santé et de la Recherche Médicale | Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor |
| KR102169346B1 (ko) * | 2019-03-27 | 2020-10-23 | 덕성여자대학교 산학협력단 | 이종이식 동물 모델의 제조방법 및 이종이식 성공 여부 판별 방법 |
| US20240368260A1 (en) | 2021-07-29 | 2024-11-07 | Institut National De La Sante Et De La Recherche Medicale | HUMANIZED ANTI-HUMAN ßIG-H3 PROTEIN AND USES THEREOF |
| WO2025068157A1 (en) * | 2023-09-25 | 2025-04-03 | Stromacare | COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER |
| WO2025224297A1 (en) * | 2024-04-26 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to tgfbi and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| EP1502114A4 (en) * | 2002-04-19 | 2006-06-07 | Regen Biotech Inc | METHOD FOR MEASURING THE PROTEIN AMOUNT $ G (B) IG-H3 AND DIAGNOSTIC KIT USING THE SAME |
| KR20060056445A (ko) | 2004-11-19 | 2006-05-24 | 주식회사 리젠 바이오텍 | 인간 βｉｇ－ｈ３에 대한 단클론 항체 |
| ITVI20050059A1 (it) * | 2005-03-04 | 2006-09-05 | Consorzio Per Gli Studi Universitari In Verona | Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali |
| EP2463657A1 (en) * | 2010-12-13 | 2012-06-13 | Université de Liège | Biomarkers, uses of biomarkers and a method of identifying biomarkers |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US9845471B2 (en) * | 2013-01-15 | 2017-12-19 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating pancreatic cancer |
| KR101515700B1 (ko) | 2013-05-15 | 2015-04-27 | 경북대학교 산학협력단 | Tgfbi를 이용한 패혈증 진단용 조성물 및 이를 이용한 패혈증 예방 또는 치료용 약학적 조성물과 이의 스크리닝 방법 |
| WO2015200790A2 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
| CN116327915A (zh) | 2015-04-03 | 2023-06-27 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| ES2911038T3 (es) * | 2016-03-15 | 2022-05-17 | Inst Nat Sante Rech Med | Procedimiento temprano y no invasivo para evaluar el riesgo de un sujeto de tener adenocarcinoma ductal pancreático y procedimientos de tratamiento de dicha enfermedad |
| KR102082344B1 (ko) * | 2018-06-21 | 2020-02-27 | 조성은 | 담도암의 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
-
2017
- 2017-03-15 ES ES17710554T patent/ES2911038T3/es active Active
- 2017-03-15 ES ES20195759T patent/ES2944259T3/es active Active
- 2017-03-15 KR KR1020217014527A patent/KR102408161B1/ko active Active
- 2017-03-15 PL PL17710554T patent/PL3430404T3/pl unknown
- 2017-03-15 KR KR1020187027907A patent/KR102402444B1/ko active Active
- 2017-03-15 DK DK20195759.4T patent/DK3779447T3/da active
- 2017-03-15 EP EP17710554.1A patent/EP3430404B1/en active Active
- 2017-03-15 WO PCT/EP2017/056150 patent/WO2017158043A1/en not_active Ceased
- 2017-03-15 PL PL20195759.4T patent/PL3779447T3/pl unknown
- 2017-03-15 JP JP2018548412A patent/JP6903680B2/ja active Active
- 2017-03-15 HR HRP20220335TT patent/HRP20220335T1/hr unknown
- 2017-03-15 EP EP20195759.4A patent/EP3779447B1/en active Active
- 2017-03-15 FI FIEP20195759.4T patent/FI3779447T3/fi not_active Application Discontinuation
- 2017-03-15 US US16/081,462 patent/US11740243B2/en active Active
- 2017-03-15 DK DK17710554.1T patent/DK3430404T3/da active
- 2017-03-15 HR HRP20230391TT patent/HRP20230391T1/hr unknown
-
2021
- 2021-04-12 JP JP2021067346A patent/JP7569741B2/ja active Active
-
2023
- 2023-01-12 JP JP2023003171A patent/JP2023052360A/ja active Pending
- 2023-07-07 US US18/348,398 patent/US12140594B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ng et al. | Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma | |
| Luo et al. | Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression | |
| Amornsupak et al. | Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells | |
| Xu et al. | CXCR4 overexpression is correlated with poor prognosis in colorectal cancer | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| Kaunisto et al. | NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| Mejías-Luque et al. | Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors | |
| Wang et al. | MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma | |
| Zhen et al. | Knockdown of SNHG8 repressed the growth, migration, and invasion of colorectal cancer cells by directly sponging with miR-663 | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| Fukuta et al. | Impact of preoperative cachexia on postoperative length of stay in elderly patients with gastrointestinal cancer | |
| Shen et al. | LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer | |
| Gharib et al. | Investigating the diagnostic performance of HOTTIP, PVT1, and UCA1 long noncoding RNAs as a predictive panel for the screening of colorectal cancer patients with lymph node metastasis | |
| Liu et al. | FGA inhibits metastases and induces autophagic cell death in gastric cancer via inhibiting ITGA5 to regulate the FAK/ERK pathway | |
| Liu et al. | The BRAF activated non‐coding RNA: A pivotal long non‐coding RNA in human malignancies | |
| JP2014531020A5 (enExample) | ||
| Yang et al. | Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma | |
| HRP20220335T1 (hr) | Rani i neinvazivni postupak za procjenu rizika kod nekog subjekta od obolijevanja od duktalnog adenokarcinoma gušterače i postupci za liječenje takve bolesti | |
| Yang et al. | Biological role of long non-coding RNA FTX in cancer progression | |
| Alqosaibi et al. | Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells | |
| MY209272A (en) | Use of anti-pd-1 antibody in preparation of medicament for treating solid tumors | |
| Chen et al. | Clinical and prognostic significance of Arl4c expression in colorectal cancer | |
| Xu et al. | Targeting peroxisome proliferator-activated receptor-β/δ in colon cancer: how to aim? |